SSgA Funds Management, Inc. recently announced the acquisition of new stake in Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR). The institutional investor has increased its shareholding in the Healthcare company by 4.13% to 4.29 million shares with purchase of 0.17 million shares. This fresh investment now brings its stake to 4.22% valued currently at $185.49 million. In addition, Fidelity Management & Research Co. raised its holdings by 0.93 million to 2.81 million shares. And Northern Trust Investments, Inc.(. has lifted its position by 4.28% or 66478.0 shares – to 1.62 million shares.
With over 1.09 million Arrowhead Pharmaceuticals Inc. (ARWR) shares trading Tuesday and a closing price of $48.75 on the day, the dollar volume was approximately $53.31 million. The shares have shown a positive weekly performance of 2.98% and its price on 07/21/20 lost nearly -4.92%. Currently, there are 101.65M common shares owned by the public and among those 99.05M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for ARWR have a consensus price objective of $62.56. The analysts have set the share’s price value over the next 12 months at a high of $81.00 and a low of $29.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Arrowhead Pharmaceuticals Inc. stock is 2.00 for the next 12 months. The average price target is 21.5% above its last price level and an upside to the estimated low will see the stock lose -68.1% over that period. But an upside of 39.81% will see the stock hit the forecast high price target while mean target price for the stock is $62.00.
Insiders at the company have transacted a total of 111 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 46 of these insider trades were purchases, accounting for 1,768,028 shares. Insider sales of the common stock occurred on 65 occasions, with total insider shares sold totaling 1,056,104 shares.
The top 3 mutual fund holders in Arrowhead Pharmaceuticals Inc. are Invesco Oppenheimer Global Opport, Vanguard Total Stock Market Index, and iShares Core S&P Mid Cap ETF. Invesco Oppenheimer Global Opport owns 3.0 million shares of the company’s stock, all valued at over $129.57 million. Vanguard Total Stock Market Index bought 36184.0 shares to see its total holdings expand to 2.76 million shares valued at over $119.29 million and representing 2.71% of the shares outstanding. iShares Core S&P Mid Cap ETF now owns shares totaling to 2.68% of the shares outstanding.
Shares of Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) opened at $51.75, up $0.48 from a prior closing price of $51.27. However, the script later closed the day at $48.75, down -4.92%. The company’s stock has a 5-day price change of 2.98% and 33.12% over the past three months. ARWR shares are trading -23.14% year to date (YTD), with the 12-month market performance up to 62.61% higher. It has a 12-month low price of $19.51 and touched a high of $73.72 over the same period. Currently, 1.09 million shares have been traded, compared to an average intraday trading volume of 1.17 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.96%, 25.96%, and 15.45% respectively.
Institutional ownership of Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares accounts for 65.50% of the company’s 101.65M shares outstanding. Mutual fund holders own 38.58%, while other institutional holders and individual stakeholders account for 5.28% and 23.34% respectively.
It has a market capitalization of $4.96B and a beta (3y monthly) value of 1.83. The stock’s trailing 12-month PE ratio is 492.42, while the earnings-per-share (ttm) stands at $0.10. The company has a PEG of 67.18 and a Quick Ratio of 5.90 with the debt-to-equity ratio at 0.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.59% over the week and 5.72% over the month.
Analysts forecast that Arrowhead Pharmaceuticals Inc. (ARWR) will achieve an EPS of -$0.11 for the current quarter, -$0.18 for the next quarter and -$0.97 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.41 while analysts give the company a high EPS estimate of $0.65. Comparatively, EPS for the current quarter was $0.21 a year ago. Earnings per share for the fiscal year are expected to increase by 205.90%, and -90.20% over the next financial year. EPS should shrink at an annualized rate of 7.33% over the next five years, compared to 20.60% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate Arrowhead Pharmaceuticals Inc. (ARWR) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 2 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ARWR, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on May 13, 2020, with the firm’s price target at $62. Oppenheimer coverage for the Arrowhead Pharmaceuticals Inc. (ARWR) stock in a research note released on May 08, 2020 offered a Outperform rating with a price target of $58. Cantor Fitzgerald was of a view on April 15, 2020 that the stock is Overweight, while SVB Leerink gave the stock Mkt Perform rating on March 24, 2020, issuing a price target of $29. Goldman on their part issued Neutral rating on March 17, 2020.